» Articles » PMID: 21795470

The Effects of NS5A Inhibitors on NS5A Phosphorylation, Polyprotein Processing and Localization

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2011 Jul 29
PMID 21795470
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a multi-functional protein that is expressed in basally phosphorylated (p56) and in hyperphosphorylated (p58) forms. NS5A phosphorylation has been implicated in regulating multiple aspects of HCV replication. We recently reported the identification of a class of compounds that potently inhibit HCV RNA replication by targeting NS5A. Although the precise mechanism of inhibition of these compounds is not well understood, one activity that has been described is their ability to block expression of the hyperphosphorylated form of NS5A. Here, we report that an NS5A inhibitor impaired hyperphosphorylation without affecting basal phosphorylation at the C-terminal region of NS5A. This inhibitor activity did not require NS5A domains II and III and was distinct from that of a cellular kinase inhibitor that also blocked NS5A hyperphosphorylation, results that are consistent with an inhibitor-binding site within the N-terminal region of NS5A. In addition, we observed that an NS5A inhibitor promoted the accumulation of an HCV polyprotein intermediate, suggesting that inhibitor binding to NS5A may occur prior to the completion of polyprotein processing. Finally, we observed that NS5A p56 and p58 separated into different membrane fractions during discontinuous sucrose gradient centrifugation, consistent with these NS5A phosphoforms performing distinct replication functions. The p58 localization pattern was disrupted by an NS5A inhibitor. Collectively, our results suggest that NS5A inhibitors probably impact several aspects of HCV expression and regulation. These findings may help to explain the exceptional potency of this class of HCV replication complex inhibitors.

Citing Articles

Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus.

Liman W, Oubahmane M, Lahcen N, Hdoufane I, Cherqaoui D, Daoud R Sci Rep. 2024; 14(1):31655.

PMID: 39738127 PMC: 11686136. DOI: 10.1038/s41598-024-80082-1.


The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.

Bobardt M, Ramirez C, Baum M, Ure D, Foster R, Gallay P PLoS One. 2021; 16(5):e0251934.

PMID: 34014993 PMC: 8136729. DOI: 10.1371/journal.pone.0251934.


Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation.

Schenk C, Meyrath M, Warnken U, Schnolzer M, Mier W, Harak C J Virol. 2018; 92(24).

PMID: 30258001 PMC: 6258934. DOI: 10.1128/JVI.00737-18.


Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D Antimicrob Agents Chemother. 2018; 62(11).

PMID: 30150466 PMC: 6201069. DOI: 10.1128/AAC.01280-18.


Adapted HCV JFH1 variant is capable of accommodating a large foreign gene insert and allows lower level HCV replication and viral production.

Wang Q, Hagedorn C, Liu S Int J Biol Sci. 2018; 14(10):1211-1220.

PMID: 30123070 PMC: 6097470. DOI: 10.7150/ijbs.27411.